SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ANL

Adlai Nortye Group Ltd. (NASDAQ:ANL)

SG · Delayed Price · Currency is USD
Healthcare · Biotechnology
$8.55-$0.51 (-5.63%)
 
Market cap
$454M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 29, 2023
Market Cap$453.83M+506.4%
Revenue (ttm)$19.68M
Net Income-$22.53M+47.1%
EPS-$1.95+46.4%
Shares Out53.08M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume380,645
Open$8.79
Previous Close$9.06
Day's Range$8.36 - $8.98
52-Week Range$0.88 - $17.25
Beta1.16
AnalystsBuy
Price Target$37.33(+336.61%)
Earnings DateMar 3, 2027

About ANL

Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.

Address
77 Robinson Road, #20-01, Robinson 77, Singapore, 068896, SG
Market Cap
454 million
Employees
109
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$411.19K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $33.33 (+289.8%)

1 firm rating ANL in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Weak
From ANL’s reported statements · Q2 2026 (trailing 12 months)

Next catalysts

1 Day
-5.63%
5 Days
-19.34%
1 Month
-19.19%
6 Months
-28.27%
1 Year
+506.38%

$ANL stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ANL holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ANL's directors and management

Net Shares Purchased by Insiders−30k−15k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ANL Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ANL patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ANL from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ANL

CANCTema Oncology ETF$889.76K
EWXState Street SPDR S&P Emerging Markets Small Cap ETF$262.74K
BBCVirtus Biotech Clinical Trials ETF$234.36K
GXCState Street SPDR S&P China ETF$65.23K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ANL’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
7
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-47.0 since Aug 27
0255075100Aug 27 — Insider Score 47.0Aug 28 — Insider Score 47.0Aug 29 — Insider Score 47.0Aug 30 — Insider Score 47.0Aug 31 — Insider Score 47.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 29.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 27Sep 15Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BBCVirtus Biotech Clinical Trials ETF0.78%
CANCTema Oncology ETF0.52%
EWXState Street SPDR S&P Emerging Markets Small Cap ETF0.05%
APIEActivePassive International Equity ETF0.00%

Weight is the stock’s share of each fund’s holdings.